Listed

IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 6, 2019 and accepted by EDGAR at Nov 5, 2019, 17:53 ET.

Share

Management's discussion and analysis

As filed, 18,088 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The purpose of this Management’s Discussion and Analysis (“MD&A”) is to provide an understanding of the Company's consolidated financial condition, results of operations and cash flows, and should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q for the three- months and six-months ended September 30, 2019, and the Annual Report on Form 10-K for the fiscal year ended March 31, 2019 filed with the SEC on June 14, 2019. The Company’s actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in the “Forward-Looking Statements” and “Risk Factors” sections, as well as discussed elsewhere in this report. The risks and uncertainties can cause actual results to differ significantly from those in our forward-looking statements or implied in historical results and trends. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

Our primary source of revenue in the three- months and six-months ended September 30, 2019 and the three- months and six -months ended September 30, 2018 is from our Infrastructure Business. The Company’s Infrastructure Business, involves:

(i) Short-term rental of heavy construction equipment including bulldozers, excavators, rollers and pavers, among others.

(ii) Bidding and execution of construction contracts. Our subsidiary TBL, with over 30 years of experience with infrastructure projects, recently began work on a construction project, building and modifying a road in Kerala, India. In January 2019, TBL received a construction contract for the building of a National Highway Authority of India (“NHAI”) sponsored local highway.

(iii) The purchase and resale of physical commodities, used in infrastructure.

Our second line of business is the Plant and Cannabinoid Business, which stems from plant material and cannabinoids produced by the cannabis plant, in accordance with applicable laws and regulations. The Company’s strategy is to create, build, and manage several brands of plant and cannabinoid-based products and therapies, such as Hyalolex™, Serosapse™, Natrinol™, and Holi Hemp™, among others, in accordance with laws and regulations applicable to the location where such products and components are located from time to time. As part of this strategy, the Company expects to secure the quality, quantity and cost of its supply chain by setting up and controlling facilities that grow and extract the active ingredients for our products. In addition, we are also exploring acquisitions, investments, or the creation of joint ventures with competitive and complementary businesses, products and technologies. As market demand for hemp grows, as predicted by some analysts, we expect to sell these and other products on a retail and wholesale basis in accordance with existing and future state and federal laws and regulations, including those propounded by the U.S. Food and Drug Administration, as they are enforced, enacted, modified, and/or amended to address the growing cannabinoid industry. As previously announced, our product mix is expected to include hemp/CBD-infused drinks; tinctures; full spectrum oil; hemp distillate; and hemp isolate, among others. The Company operates its Plant and Cannabinoid Business in compliance with federal, state, and local laws and applicable regulations and only where it is legal to do so.

Results of Operations for the three months ended

September 30, 2019 and September 30, 2018

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the three months ended September 30, 2019 and September 30, 2018:

Statement of Operations (in thousands)

Three-months ended September 30, 2019 ($) 2018 ($) Change ($) Percent Change
Revenue 1,821 811 1,010 125%
Cost of revenue (1,793) (793) (1,000) 126%
General and administrative expenses (1,094) (595) (499) 84%
Research & development expenses (222) (278) 56 (20)%
Operating loss (1,288) (855) (433) 51%
Other income/(expense), net 109 (4) 113 (2,825)%
Net Loss (1,179) (859) (320) 37%

| September 30, 2019 Form 10-Q

Revenues– Revenue is primarily derived from our Infrastructure Business for the three months ended September 30, 2019 and the three months ended September 30, 2018. Revenue amounted to approximately $1,821 thousand and $811 thousand, for the three months ended September 30, 2019 and September 30, 2018 respectively, representing an increase of $1,010 thousand or 125%. The increase in revenue is from an increase in the sales of infrastructure related physical commodities. In the three months ended March 31, 2019, we also commenced sales in the Plant and Cannabinoid Business, which contributed $274 thousand in revenue, net in the three months ended September 30, 2019.

Cost of revenue– Cost of revenue is primarily from our Infrastructure Business in the three months ended September 30, 2019 and the three months ended September 30, 2018. Cost of revenue amounts to approximately $1,793 thousand for the three months ended September 30, 2019 compared to $793 thousand in the three months ended September 30, 2018, an increase of approximately $1,000 thousand or 126%. This increase in cost of revenue is attributable to increased purchases of physical commodities, with the margins remaining stable. The Plant and Cannabinoid Business, contributed $266 thousand in cost of revenue in the three months ended September 30, 2019.

General and administrative expenses – These General and administrative expenses consist primarily of employee-related expenses, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any. General and administrative expenses increased by approximately $499 thousand or 84% to $1,094 thousand for the three months ended September 30, 2019 from $595 thousand for the three months ended September 30, 2018. Of the $499 thousand increase, legal & professional fees, stemming primarily from shareholder lawsuits, amounted to approximately $291 thousand.

*Research and Development expenses - Research and Development expenses (“*R&D”) expenses are attributed to our Plant and Cannabinoid Business. The R&D expenses decreased approximately $56 thousand or 20%, to $222 thousand for the three months ended September 30, 2019, compared to $278 thousand for the three months ended September 30, 2018. The cost associated with this work is mostly research comprising of plant extracts that could be productized and data to support the efficacy of the extracts. All research and development costs are expensed in the quarter in which they are incurred.

Other Income/(expense), net – Other net income increased by approximately $113 thousand or 2,825% during the three months ended September 30, 2019. The total other income/(expense) for the three months ended September 30, 2019 and the three months ended September 30, 2018 is approximately $109 thousand and ($4) thousand, respectively. In the three months ended September 30, 2019, such amount includes interest income/(expense), rental income and dividend income, net.

Results of Operations for the six months ended

September 30, 2019 and September 30, 2018

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the six months ended September 30, 2019 and September 30, 2018:

Six-months ended September 30, 2019 ($) 2018 ($) Change ($) Percent Change
Revenue 3,470 2,289 1,181 52%
Cost of revenue (3,401) (2,229) (1,172) 53%
General and administrative expenses (2,343) (1,149) (1,194) 104%
Research & development expenses (469) (278) (191) 69%
Operating loss (2,743) (1,367) (1,376) 101%
Other income/(expense), net 185 (4) 189 (4,725)%
Net Loss (2,558) (1,371) (1,187) 87%

Revenues– Revenue is primarily derived from our Infrastructure Business for the six months ended September 30, 2019 and the six months ended September 30, 2018. Revenue amounted to approximately $3,470 thousand and $2,289 thousand, for the six months ended September 30, 2019 and September 30, 2018 respectively, representing an increase of $1,181 thousand or 52%. The increase in revenue is from an increase in the sales of infrastructure related physical commodities. In the three months ended March 31, 2019, we also commenced sales in the Plant and Cannabinoid Business, which contributed $379 thousand in revenue, net in the six months ended September 30, 2019.

Cost of revenue– Cost of revenue is primarily from our Infrastructure Business in the six months ended September 30, 2019 and the six months ended September 30, 2018. Cost of Revenue amounts to approximately $3,401 thousand for the six months ended September 30, 2019 compared to $2,229 thousand in the six months ended September 30, 2018, an increase of approximately $1,172 thousand or 53%. This increase in cost of revenue is attributable to increased purchases of physical commodities, with the margins remaining stable. The Plant and Cannabinoid Business, contributed $357 thousand in cost of revenue in the six months ended September 30, 2019.

General and administrative expenses – These General and administrative expenses consist primarily of employee-related expenses, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any. General and administrative expenses increased by approximately $1,194 thousand or 104% to $2,343 thousand for the six months ended September 30, 2019 from $1,149 thousand for the six months ended September 30, 2018. Of the $1,194 thousand increase, legal & professional fees, stemming primarily from shareholder lawsuits, amounted to about $574 thousand.

*Research and Development expenses -Research and Development expenses (“*R&D”) expenses are attributed to our Plant and Cannabinoid Business. The expenses increased approximately $191 thousand or 69%, to $469 thousand for the six months ended September 30, 2019, compared to $278 thousand for the six months ended September 30, 2018. The cost associated with this work is mostly research comprising of plant extracts that could be productized and data to support the efficacy of the extracts. All research and development costs are expensed in the quarter in which they are incurred.

Other Income/(expense), net – Other income increased by approximately $189 thousand or 4,725% during the six months ended September 30, 2019. The total other income/(expense) for the six months ended September 30, 2019 and the six months ended September 30, 2018 is approximately $185 thousand and ($4) thousand, respectively. In the six months ended September 30, 2019, such amount includes interest income/(expense), rental income, dividend income, and a non-operating settlement expense.

Liquidity and Capital Resources

This liquidity and capital resources discussion compares the unaudited consolidated Company financials.

(in thousands, unaudited)

As of September 30, 2019 ($) As of March 31, 2019 ($) Change Percent Change
Cash, cash equivalents and marketable securities 14,063 25,610 (11,547) 45%
Working capital 22,270 25,845 (3,575) 14%

Cash and cash equivalents

Cash and cash equivalents decreased by approximately $11,547 thousand to $14,063 thousand in the six months ended September 30, 2019 from $25,610 thousand in March 31, 2019, a decrease of approximately 45%. The major decrease is due to investments of approximately $5,039 thousand in mutual funds, $2,049 thousand in purchase of property, plant and equipment and $2,860 thousand in inventory in the six months ended September 30, 2019.

Summary of Cash flows

(in thousands, unaudited)

Six Months Ended September 30, 2019 ($) 2018 ($) Change ($) Percent Change
Cash used in operating activities (4,444) (851) (3,593) 422%
Cash used in investing activities (7,111) (16) (7,095) 44,344%
Cash provided by financing activities 18 5,683 (5,665) (100)%
Effects of exchange rate changes on cash and cash equivalents (10) (66) 56 (85)%
Net decrease in cash and cash equivalents (11,547) 4,750 (16,297) (343)%
Cash and Cash Equivalents at the beginning of period 25,610 1,658 23,952 1,445%
Cash and cash equivalents at the end of the period 14,063 6,408 7,655 119%

| September 30, 2019 Form 10-Q

Operating Activities

Net cash used in operating activities for the six months ended September 30, 2019 was $4,444 thousand. Cash was consumed from continuing operations, with the net loss of $2,558 thousand, non-cash items totaling $406 thousand, consisting of a depreciation charge of $45 thousand and stock-based expenses totaling $361 thousand and changes in working capital accounts had a negative impact of $2,292 thousand on cash.

Net cash used in operating activities for the six months ended September 30, 2018 was $851 thousand. Cash was consumed from continuing operations, with the net loss of $1,371 thousand, non-cash items totaling $446 thousand, consisting of a depreciation charge of $29 thousand and stock-based expenses totaling $417 thousand and changes in working capital accounts had an impact of $74 thousand on cash

Investing Activities

Net cash used in investing activities during the six months ended September 30, 2019 was $7,111 thousand which is comprised of approximately $2,049 thousand for purchase of office space, plant and equipment among others, $5,039 thousand for investment in a money market mutual fund and $23 thousand for the acquisition and filing of patents.

Net cash used in investing activities during the six months ended September 30, 2018 was $16 thousand which is comprised of approximately $3 thousand for purchase of plant and equipment among others, and $13 thousand for the acquisition and filing of patents.

Financing Activities

Cash provided by financing activities of approximately $18 thousand during the six months ended September 30, 2019 consisted of share options previously issued to advisor.

Cash provided by financing activities of approximately $5,683 thousand during the six months ended September 30, 2018 consisted of raising funds through a public offering amounting to $5,885 thousand and repayment of loan amounting to $202 thousand.

Off-Balance Sheet Arrangements

We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency forward contracts. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in an unconsolidated entity that provides financing, liquidity, market risk or credit support to us or that engages in leasing, hedging or research and development services with us.

Critical Accounting Policies

While all accounting policies impact the financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require Management’s most subjective or complex judgments and estimates. Our Management believes the policies that fall within this category are the policies on revenue recognition, inventory, accounts receivable, income taxes, foreign currency translation, impairment of long-lived assets and investments, stock-based compensation, and cybersecurity. We have a cybersecurity policy in place and tighter cybersecurity measures to safeguard against hackers. There were no impactful breaches in cybersecurity in the six months ended September 30, 2019.

Please see our disclosures in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report, in the Notes to the Audited Consolidated Financial Statements in Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2019 filed with the SEC on June 14, 2019, as well as Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations, on the same annual report, for a discussion of all our critical and significant accounting policies.

Recent Accounting Pronouncements

The recent accounting pronouncements are discussed in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report and in the Notes to the Audited Consolidated Financial Statements in Part II of our Annual Report on Form 10-K for fiscal year ended March 31, 2019 filed with the SEC on June 14, 2019.

Controls and procedures

As filed, 2,363 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to Management, including our Chief Executive Officer and Principal Financial Officer (our principal executive officer and principal financial officer, respectively), as appropriate, to allow for timely decisions regarding required disclosure.

Our Management, including the Chief Executive Officer and Principal Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed in the reports filed or submitted by us under the Exchange Act was recorded, processed, summarized and reported within the requisite time periods and that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

Our Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our “internal control over financial reporting” as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting occurred during the three months ended September 30, 2019 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no changes in our internal control over financial reporting during the three months ended September 30, 2019 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Risk factors

As filed, 9,238 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should carefully consider the following risk factors, and the risk factors identified in the Company’s 2019 annual report on Form 10-K, filed with the SEC on June 14, 2019, the Risk Factors identified in our Form 10-Q filed with the SEC on August 9, 2019, together with all other information included in this report in evaluating our company and our common stock. If any of the following risks and uncertainties develops into actual events, they could have a material adverse effect on our business, financial condition or results of operations. In that case, the trading price of our common stock and other securities also could be adversely affected. We make various statements in this section, which constitute “forward-looking statements.” See “Forward-Looking Statements.”

The Company incorporates by reference herein all Risk Factors identified in our 2019 annual report on Form 10-K, filed with the SEC on June 14, 2019 and the Risk Factors identified in our Form 10-Q filed with the SEC on August 9, 2019. Additionally, risks and uncertainty of which we are unaware or which currently we deem immaterial also may become important factor that affects us. The additional risk factors have been mentioned below:

Pending or future legal proceedings may have a material adverse effect on our business, operating results and financial condition. We may in the future face risks of litigation and liability claims, the extent of such exposure can be difficult or impossible to estimate and which can negatively impact our financial condition and results of operations.

Our operations are subject to numerous U.S., Indian and Hong Kong laws and regulations relating to the protection of the public and necessary disclosures in regard to financial services. Liability under these laws involves inherent uncertainties. Violations of financial regulation laws are subject to civil, and, in some cases, criminal sanctions. Although we are not aware of any compliance related issues, we may not have been, or may not be, at all times, in complete compliance with all requirements, and we may incur costs or liabilities in connection with such requirements. We may also incur unexpected interruptions to our operations, administrative injunctions requiring operation stoppages, fines and other penalties, which could negatively impact our financial condition and results of operations.

As of September 30, 2019, the Company and several of its officers and directors are parties to three (3) shareholder lawsuits. See Item 1, Legal Proceedings of this report for further information. There can also be no assurance that any insurance coverage we take will be adequate or that we will prevail in any future cases. We can provide no assurance that we will be able to obtain liability insurance that would protect us from any such lawsuits. In the event that are not covered by insurance, our management could expend significant time and resources addressing any such issues.

On July 31, 2019, the Company and its officers and directors reached a preliminary agreement with the plaintiffs in the three shareholder derivative suits to resolve all such derivative suits. Settlement is pending agreement on specific final terms and approval by the United States District Court for the District of Maryland. There can be no guarantee that the parties will reach agreement on specific final terms to resolve the derivative suits or that any settlement reached will be approved by the court. On October 11, 2019, the Company and its officers and directors filed a motion to dismiss the Tchatchou litigation identified in Item 1, Legal Proceedings, of this report. There can be no guarantee that the court will grant the motion to dismiss. The legal fees necessary to defend against these lawsuits, or any other future litigation filed against the Company, can be significant, impacting the Company’s overall bottom line when not covered by insurance or where the fees exceed the Company’s insurance policy limits.

Continued listing on the NYSE is an operating risk for the Company.

As previously disclosed, on October 29, 2018, NYSE suspended trading of the Company’s common stock and commenced proceedings to delist the Company’s stock from trading on the Exchange. After a successful appeal, the Company’s stock was relisted for trading on February 26, 2019. However, given the current regulatory environment for hemp-based products, there remains risk with respect to the Company’s ability to maintain its listing with the NYSE. This risk may limit the Company’s ability to pursue other business opportunities and a delisting by the NYSE could impact the liquidity of the Company’s common stock.

Extreme weather conditions, crop diseases, pests and fluctuations in market demand can create substantial seasonal volatility for our business and results of operations.

The company’s Plant and Cannabinoid Business is seasonal and is subject to weather conditions that affect hemp prices and crop yields. Our production is also vulnerable to crop diseases and pest infestations, which may vary in severity, depending on the stage of production at the time of infection or infestation, the type of treatment applied and climatic condition. We take into account the possibility of the occurrence of these adverse seasonal weather conditions in making our production plans to mitigate such risks. However, such events may occur at any time of the year, and the occurrence of any of these events may create the volatility for our business and results of operations.

The market prices of hemp crops and agricultural produce are constantly affected by both demand and supply cycle of the hemp industry. As a result, movements of the market prices would have significant impact on IGC’s earnings. Whilst efforts have been made by Management to implement certain strategies, there can be no assurance that IGC will be fully shielded from the negative effects of cyclical movements of the market prices of crops and agricultural produce.

We are dependent upon regulatory approvals and fixed term licenses for our ability to grow, harvest, process, and transport hemp and other products derived therefrom.

Our current authorization for growing, harvesting, processing and transport of cannabis is valid for a single growing season at a time and notification to AZDA is needed to renew the license for subsequent growing seasons. All licenses are subject to ongoing compliance and reporting requirements and renewal.

There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the hemp market or any particular product, or consistent with currently held views.

The Management believes that the hemp industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the hemp produced. Consumer perception can be significantly influenced by scientific research or findings, regulatory proceedings, litigation, media attention and other publicity regarding the consumption of hemp products. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the hemp industry and demand for its products and services, which could affect the Company’s business, financial condition and results of operations and cash flows. The Company’s dependence upon consumer perception means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, its business, financial condition, results of operations and cash flows. Further, adverse publicity, reports or other media attention regarding the safety, efficacy and quality of hemp in general, or the Company’s products specifically, or associating the consumption of cannabis with illness or other negative effects or events, could have a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers’ failure to consume such products legally, appropriately, or as directed. Unfavorable research reports, newspaper articles, social media, testimonials can adversely affect our sales and consequently our stock price.

In addition, parties outside of the hemp industry with which the Company does business may perceive that they are exposed to reputational risk as a result of the Company’s hemp related business activities. For example, the Company could receive a notification from a financial institution advising it that they would no longer maintain banking relationships with those in the hemp industry. The Company may, in the future, have difficulty establishing or maintaining bank accounts or other business relationships that it needs to operate its business. Failure to establish or maintain business relationships could have a material adverse effect.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$1.8mus-gaap:Revenues
Revenue6 months2019-04-01 to 2019-09-30$3.5mus-gaap:Revenues
Cost of revenue3 months2019-07-01 to 2019-09-30$1.8mus-gaap:CostOfRevenue
Cost of revenue6 months2019-04-01 to 2019-09-30$3.4mus-gaap:CostOfRevenue
Gross profit3 months2019-07-01 to 2019-09-30$28.0kus-gaap:GrossProfit
Gross profit6 months2019-04-01 to 2019-09-30$69.0kus-gaap:GrossProfit
Research and development3 months2019-07-01 to 2019-09-30$222.0kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2019-04-01 to 2019-09-30$469.0kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-07-01 to 2019-09-30$1.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2019-04-01 to 2019-09-30$2.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-07-01 to 2019-09-30−$1.3mus-gaap:OperatingIncomeLoss
Operating income6 months2019-04-01 to 2019-09-30−$2.7mus-gaap:OperatingIncomeLoss
Income tax3 months2019-07-01 to 2019-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax6 months2019-04-01 to 2019-09-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-07-01 to 2019-09-30−$1.2mus-gaap:NetIncomeLoss
Net income6 months2019-04-01 to 2019-09-30−$2.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30−$0.03us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2019-04-01 to 2019-09-30−$0.06us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2019-04-01 to 2019-09-30−$4.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2019-04-01 to 2019-09-30$2.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-09-30$14.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$23.9mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$32.9mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$1.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$1.6mus-gaap:Liabilities
Short-term borrowingsAt period end2019-09-30$50.0kus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2019-09-30$31.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001185185-19-001517. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.